Precigen, Inc. PGEN
Set alert
As of Nov 2, 11:18 AM ET
- YTD
- +23.09%
- 1 year
- +24.28%
- Open
- 5.32
- Prev close
- 6.94
- Mkt cap
- 1.83B
- Vol
- 7.25M
- Avg vol
- 5.29M
- EPS
- -1.04
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 4.91
- High
- 5.36
- Forward P/E
- -31.55
- Beta
- 0.92
- Short ratio
- 8.53
- Inst. own
- 72.87%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 4, 2026
- 50-d avg
- 7.23
- 200-d avg
- 5.26
- 1y target
- 13.65
5D chart
Signals (94)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Nov 2, 10:15 AM | 1 hour ago |
| SMA: Bearish | Nov 2, 9:30 AM | 1 hour ago |
| SMA: Bearish | Nov 2, 9:30 AM | 1 hour ago |
| MACD: Sell Signal | Nov 2, 9:30 AM | 1 hour ago |
| RSI: Oversold | Nov 2, 9:30 AM | 1 hour ago |
| RSI: Overbought | Oct 30, 3:50 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 3:25 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:20 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:20 PM | 2 days ago |
| SMA: Bearish | Oct 30, 3:10 PM | 2 days ago |
| SMA: Bearish | Oct 30, 3:10 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:05 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:05 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 2:55 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:50 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:50 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 2:35 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 1:35 PM | 2 days ago |
| RSI: Overbought | Oct 30, 1:15 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 12:40 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:35 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:35 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 11:40 AM | 3 days ago |
| SMA: Bearish | Oct 30, 11:30 AM | 3 days ago |
| RSI: Overbought | Oct 30, 11:05 AM | 3 days ago |
| SMA: Bullish | Oct 30, 10:40 AM | 3 days ago |
| MACD: Buy Signal | Oct 30, 10:35 AM | 3 days ago |
| SMA: Bearish | Oct 30, 10:05 AM | 3 days ago |
| SMA: Bullish | Oct 30, 10:00 AM | 3 days ago |
| SMA: Bearish | Oct 30, 9:40 AM | 3 days ago |
| MACD: Sell Signal | Oct 30, 9:40 AM | 3 days ago |
| MACD: Buy Signal | Oct 30, 9:30 AM | 3 days ago |
| SMA: Bearish | Oct 29, 3:55 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 3:55 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 3:45 PM | 3 days ago |
| SMA: Bearish | Oct 29, 3:40 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 3:40 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 3:35 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:30 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:40 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:30 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:25 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:10 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:05 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:00 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 12:50 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 12:45 PM | 3 days ago |
| RSI: Overbought | Oct 29, 12:40 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:15 PM | 4 days ago |
| MACD: Sell Signal | Oct 29, 11:50 AM | 4 days ago |
| SMA: Bearish | Oct 29, 11:40 AM | 4 days ago |
| RSI: Overbought | Oct 29, 10:50 AM | 4 days ago |
| RSI: Overbought | Oct 29, 10:20 AM | 4 days ago |
| RSI: Overbought | Oct 29, 9:45 AM | 4 days ago |
| SMA: Bullish | Oct 29, 9:30 AM | 4 days ago |
| SMA: Bullish | Oct 29, 9:30 AM | 4 days ago |
| SMA: Bearish | Oct 28, 3:55 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:55 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:30 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 3:30 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 3:20 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:00 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:50 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:35 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 2:30 PM | 4 days ago |
| RSI: Oversold | Oct 28, 2:05 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:35 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:25 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:20 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:20 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:10 PM | 5 days ago |
| SMA: Bullish | Oct 28, 12:10 PM | 5 days ago |
| MACD: Sell Signal | Oct 28, 11:35 AM | 5 days ago |
| SMA: Bearish | Oct 28, 11:25 AM | 5 days ago |
| RSI: Overbought | Oct 28, 10:50 AM | 5 days ago |
| SMA: Bearish | Oct 28, 10:25 AM | 5 days ago |
| MACD: Buy Signal | Oct 28, 9:55 AM | 5 days ago |
| SMA: Bullish | Oct 28, 9:50 AM | 5 days ago |
| SMA: Bullish | Oct 28, 9:50 AM | 5 days ago |
| MACD: Sell Signal | Oct 28, 9:35 AM | 5 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 5 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 3:35 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:30 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 3:20 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 3:10 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 2:55 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:30 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:25 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 2:25 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:20 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:30 PM | 5 days ago |
| SMA: Bullish | Oct 27, 11:40 AM | 6 days ago |
| SMA: Bearish | Oct 27, 11:05 AM | 6 days ago |
News
3 hours ago benzinga.com
Kosmos Energy Posts Downbeat Q3 Results, Joins Once Upon A Farm And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
U.S. futures rose, but Kosmos Energy plunged 13.6% after missing Q3 earnings and sales estimates; other stocks also fell in premarket trading.
4 hours ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Inovio Pharmaceuticals (NASDAQ:INO) shares increased by 232.0% to $2.0 during Monday's pre-market session. The company's market cap stands at $62.2 million. AngioDynamics (NASDAQ:ANGO) shares…
6 hours ago benzinga.com
Why Inovio Pharmaceuticals Shares Are Trading Higher By Over 230%; Here Are 20 Stocks Moving Premarket
Inovio shares surged 230% premarket after FDA accelerated Voceryq approval; ClearOne and 22nd Century gained, while RedCloud fell 33.5%.
2 days ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Inovio Pharmaceuticals (NASDAQ:INO) stock moved upwards by 292.6% to $2.37 during Friday's after-market session. The market value of their outstanding shares is at $79.8 million. Capricor…
4 days ago prnewswire.com
Precigen to Announce Third Quarter 2026 Financial Results and Provide Business Updates on November 4
GERMANTOWN, Md., Oct. 28, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve…
1 week ago defenseworld.net
Precigen, Inc. $PGEN Stock Sold by Iridian Asset Management LLC CT
Iridian Asset Management LLC CT lowered its stake in Precigen, Inc. (NASDAQ: PGEN) by 24.0% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and…
3 weeks ago defenseworld.net
Pyxis Oncology (NASDAQ:PYXS) & Precigen (NASDAQ:PGEN) Head to Head Analysis
Precigen (NASDAQ: PGEN - Get Free Report) and Pyxis Oncology (NASDAQ: PYXS - Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two companies…
3 weeks ago benzinga.com
Constellation Brands, Caribou Biosciences And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
U.S. stock futures fell; Constellation Brands dropped 5.1% despite beating estimates, while biotech, mining and other stocks declined premarket.
3 weeks ago zacks.com
PGEN Stock Up More Than 50% in 3 Months: Here's What You Should Know
Precigen is building momentum with Papzimeos sales growth, a European regulatory review and progress across its AdenoVerse pipeline.
4 weeks ago defenseworld.net
Comparing PTC Therapeutics (NASDAQ:PTCT) and Precigen (NASDAQ:PGEN)
Precigen (NASDAQ: PGEN - Get Free Report) and PTC Therapeutics (NASDAQ: PTCT - Get Free Report) are both mid-cap healthcare companies, but which is the better business? We will contrast the two…
1 month ago zacks.com
4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike
ABT, CORT, PGEN and BHC offer low-beta healthcare exposure as rate-hike fears and market volatility persist.
1 month ago zacks.com
Precigen (PGEN) Soars 6.3%: Is Further Upside Left in the Stock?
Precigen (PGEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase…
1 month ago zacks.com
PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential?
Precigen's Papzimeos and Ironwood's Linzess are driving growth, but competition, pipeline progress and single-product reliance shape each biotech's outlook.
1 month ago seekingalpha.com
Precigen: The FDA's Platform Technology Designation And The Institutional Crossover Effect
Precigen just received an FDA "platform technology designation" for AdenoVerse, something that validates its versatility and accelerates its pipeline. PAPZIMEOS, the first FDA-approved product from…
1 month ago benzinga.com
This Tower Semiconductor Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Analysts initiated bullish coverage on TSEM, PGEN, SPTX, PDFS and CF, setting targets of $300, $12, $46, $60 and $162.
-
1 month ago benzinga.com
B. Riley Securities Initiates Coverage On Precigen with Buy Rating, Announces Price Target of $12
B. Riley Securities analyst Yuan Zhi initiates coverage on Precigen (NASDAQ:PGEN) with a Buy rating and announces Price Target of $12.
1 month ago zacks.com
Can PGEN's AdenoVerse Pipeline Create Growth Beyond Papzimeos?
Precigen's Papzimeos is gaining commercial momentum, while its pipeline potential through the AdenoVerse platform could create new growth opportunities.
1 month ago defenseworld.net
Precigen (NASDAQ:PGEN) Hits New 1-Year High – Time to Buy?
Precigen, Inc. (NASDAQ: PGEN - Get Free Report) shares hit a new 52-week high during mid-day trading on Wednesday. The company traded as high as $8.04 and last traded at $7.89, with a volume of…
1 month ago prnewswire.com
Precigen Receives FDA Platform Technology Designation for AdenoVerse Platform
Designation has the potential to accelerate development of current and future therapies built on Precigen's AdenoVerse platform GERMANTOWN, Md., Sept. 21, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq:…
1 month ago defenseworld.net
Head-To-Head Comparison: Precigen (NASDAQ:PGEN) and Celldex Therapeutics (NASDAQ:CLDX)
Celldex Therapeutics (NASDAQ: CLDX - Get Free Report) and Precigen (NASDAQ: PGEN - Get Free Report) are both mid-cap healthcare companies, but which is the superior stock? We will contrast the two…
1 month ago zacks.com
Precigen Gains 43% in 3 Months: Is It an Indication to Buy the Stock?
PGEN's Papzimeos is driving strong early sales, while European expansion and pipeline progress could shape the stock's growth outlook.
1 month ago zacks.com
Can Papzimeos Drive Precigen's Growth Through the Rest of 2026?
Papzimeos is fueling Precigen's growth, with sales more than doubling sequentially in Q2 and demand continuing to rise in 2026.
1 month ago defenseworld.net
Legal & General Group Plc Takes $730,000 Position in Precigen, Inc. $PGEN
Legal and General Group Plc purchased a new stake in Precigen, Inc. (NASDAQ: PGEN) during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission.…
2 months ago zacks.com
Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen
Halozyme, Repligen, Iovance, Arcutis and Precigen have been highlighted in this Industry Outlook article.
2 months ago zacks.com
5 Biotech Stocks Worth Adding to Your Portfolio Now
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and…
2 months ago accessnewswire.com
Precigen's Strong Second Quarter Signals Significant Growth, Validates AdenoVerse Platform; PRGN-2009 Advances in HPV-Driven Cancers
Biotech in the News: The Longview The Company's New Drug, the First FDA-Approved Therapy for Recurrent Respiratory Papillomatosis (RRP), is Delivering Strong Commercial Traction While Highlighting…
2 months ago zacks.com
Reasons Why Investors Should Consider Betting on PGEN Stock
Precigen's Papzimeos drives rapid revenue growth, while market exclusivity, global expansion and its pipeline add long-term potential.
2 months ago benzinga.com
Toast To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Wednesday
Wall Street analysts changed outlook on top names. UBS cut Fidelity National Information target, JP Morgan downgraded Ball, Needham raised Hinge Health.
-
2 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Precigen, Raises Price Target to $18
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Precigen (NASDAQ:PGEN) with a Buy and raises the price target from $14 to $18.
2 months ago benzinga.com
Why Arista Networks Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket
Arista Networks Inc (ANET) reported strong Q2 results, with revenue of $3.04B, up 37.7% YoY. Shares rose 13% in pre-market trading.
-
2 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Bluejay Diagnostics (NASDAQ:BJDX) stock moved upwards by 42.0% to $1.42 during Tuesday's after-market session. American Well (NYSE:AMWL) stock rose 12.76% to $11.75. The market value of their…
-
3 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Precigen, Maintains $14 Price Target
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Precigen (NASDAQ:PGEN) with a Buy and maintains $14 price target.
-
5 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Precigen, Raises Price Target to $14
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Precigen (NASDAQ:PGEN) with a Buy and raises the price target from $11 to $14.
-
5 months ago benzinga.com
Precigen Says FDA Grants Orphan Drug Exclusivity For PAPZIMEOS For Treatment Of Adults With Recurrent Respiratory Papillomatosis
FDA grants orphan drug exclusivity for PAPZIMEOS for the treatment of adults with recurrent respiratory papillomatosisSeven-year period of PAPZIMEOS market exclusivity is effective through August 14,…
-
5 months ago benzinga.com
Citizens Maintains Market Outperform on Precigen, Raises Price Target to $11
Citizens analyst Jason N. Butler maintains Precigen (NASDAQ:PGEN) with a Market Outperform and raises the price target from $9 to $11.
-
5 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Precigen, Raises Price Target to $11
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Precigen (NASDAQ:PGEN) with a Buy and raises the price target from $10 to $11.
5 months ago benzinga.com
Why Cisco Shares Are Trading Higher By Over 17%; Here Are 20 Stocks Moving Premarket
Cisco Inc (NASDAQ: CSCO) beat expectations and raised guidance with $15.84B revenue and $1.06 EPS. Shares jumped 17.3% in pre-market trading.
5 months ago benzinga.com
Transcript: Precigen Q1 2026 Earnings Conference Call
Transcript: Precigen Q1 2026 Earnings Conference Call
-
5 months ago benzinga.com
Precigen Q1 EPS $(0.02), Inline, Sales $23.252M Beat $20.800M Estimate
Precigen (NASDAQ:PGEN) reported quarterly losses of $(0.02) per share which met the analyst consensus estimate. This is a 88.89 percent increase over losses of $(0.18) per share from the same period…
-
6 months ago benzinga.com
Precigen Sees Strong Early Demand for New Immunotherapy Since Launch, CMS Reimbursement Code Boosts Access as Sales Expected to Top $18M
Precigen Inc. (NASDAQ:PGEN), a commercial-stage biopharmaceutical company developing precision medicines to improve the quality of life for people suffering from recurrent respiratory papillomatosis…
-
7 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
12 Health Care Stocks Moving In Thursday's Intraday Session
7 months ago benzinga.com
Crude Oil Gains 4%; Commercial Metals Posts Mixed Q2 Results
The U.S. trade deficit in goods shrank to $87.3 billion in February from $88.6 billion in January, while exports gained 8.7% to $142.0 billion. U.S. stocks traded lower, with the Nasdaq down 1%.…
7 months ago benzinga.com
These Analysts Boost Their Forecasts On Precigen Following Q4 Results
Precigen, Inc. (NASDAQ:PGEN) reported mixed Q4 results, with a loss of 1 cent per share beating estimates but sales of $4.565 million falling short.
7 months ago benzinga.com
Olaplex, Kodiak Sciences, Precigen And Other Big Stocks Moving Higher On Thursday
Olaplex Holdings shares surge 51% after being acquired by Henkel AG & Co. KGaA. Other big gainers include Kodiak Sciences Inc and Precigen Inc.
-
7 months ago benzinga.com
Citizens Maintains Market Outperform on Precigen, Raises Price Target to $9
Citizens analyst Jason N. Butler maintains Precigen (NASDAQ:PGEN) with a Market Outperform and raises the price target from $8 to $9.
-
7 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Precigen, Raises Price Target to $10
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Precigen (NASDAQ:PGEN) with a Buy and raises the price target from $9 to $10.
7 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
12 Health Care Stocks Moving In Thursday's Pre-Market Session
7 months ago benzinga.com
Why Navan Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket
Shares of Navan Inc (NASDAQ: NAVN) spiked in pre-market trading on better-than-expected Q4 results. Gainers include EEIQ, FCHL, OLPX, SLND, PGEN, EDHL, NFGC, NEXT, and VG. Losers include MGN, CBUS,…
-
7 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session